In clinical settings, we have found a high rate of human immunodeficiency virus (HIV) drug resistance among antiretroviral-naive patients for whom the duration of infection was unknown. These high rates were most likely the result of both transmitted resistance and informal antiretroviral use, and they suggest that routine resistance testing among antiretroviral-naive patients would be a cost-effective clinical practice.
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In clinical settings, we have found a high rate of human immunodeficiency virus (HIV) drug resistance among antiretroviral-naive patients for whom the duration of infection was unknown. These high rates were most likely the result of both transmitted resistance and informal antiretroviral use, and they suggest that routine resistance testing among antiretroviral-naive patients would be a cost-effective clinical practice.
Background.
Research cohort studies of individuals who were recently infected with HIV in the United States, Canada, Mexico, and Europe have reported prevalence of transmitted drug resistance of 8.3%-20% [1] [2] [3] [4] [5] [6] . Drug-resistance testing before initiation of antiretroviral therapy in antiretroviral-naive patients is cost-effective when the prevalence rate of transmitted drug resistance is 8%-10% [7] . Most transmitted drug resistance can be detected with standard population-based pol sequencing (genotype testing) for at least 3 years after initial infection [8] [9] [10] . However, current International AIDS Society guidelines [11] recommend drug-resistance testing for individuals whose duration of HIV infection is !1 year. Because most HIV-infected individuals do not present for medical care within the first year of their infection, some clinicians continue to question the value of drug-resistance testing to help guide antiretroviral therapy for antiretroviral-naive patients [12] . This study aimed to determine the prevalence of drug resistance among antiretroviral-naive individuals with unknown duration [13] . Maximum likelihood phylogenetic analysis (using fastDNAmL [14] ) was performed on all pol sequences to determine if viruses that harbored drug-resistance-associated mutations clustered together, thereby identifying a potential transmission network of the drug-resistant virus. Phylogenetic analysis was performed with all amino acid residues included and with those residues associated with decreased drug susceptibility removed. Clustering was considered to be significant if 13 sequences with drug-resistant mutations shared a most-common recent ancestor or if the genetic diversity between any 3 or more sequences that harbored drug-resistant mutations was !4% [15] . Patient clinical data were not routinely collected as a part of this study.
Results. Nine San Diego County HIV clinics participated in this study, and 103 individuals with an unknown duration of infection received standard drug-resistance testing (performed at Monogram Biosciences [San Francisco, CA]). Twenty-six (25%) of these individuals harbored HIV strains that were resistant to at least 1 class of antiretroviral agents. Six individuals harbored HIV strains resistant to 2 classes, and 1 individual harbored an HIV strain resistant to 3 classes (table  1) . K103N was the most common drug-resistance-associated mutation, appearing in sequences obtained from 12 patients (table 2) . Phylogenetic analysis of all sequences with and without amino acid residues associated with drug resistance demonstrated no significant clustering of viral sequences that would indicate a network of transmission of drug-resistant virus (data not shown). Four of the 6 patients who had the M184V mutation-which is associated with resistance to nucleoside analogue reversetranscriptase inhibitors-also harbored drug resistance to another antiretroviral class; 3 of these patients had resistance to nonnucleoside reverse-transcriptase inhibitors and 2 had resistance to protease inhibitors as well as multiple nucleoside reverse-transcriptase inhibitor resistance-associated mutations. Two of these sequences harbored similar drug-resistance patterns and were collected from the same clinic, but were from different patients. When the clinician was questioned as to whether these 2 particular genotypes were collected under this program from antiretroviral-experienced patients by mistake, the clinician reported having questioned the patients upon receiving the results. The patients reported to their clinician that they were roommates and had both been taking a friend's HIV medications intermittently when they were feeling "poorly." Clinical data were not available for the other sequences.
Conclusion. These investigations found an extremely high prevalence of drug-resistant HIV among antiretroviral-naive patients receiving medical care in San Diego County, California, whose duration of HIV infection was unknown. This probably represents previously unrecognized transmitted and acquired drug resistance, both of which would have significant implications for the choice and effectiveness of clinician-monitored antiretroviral therapy.
This study demonstrates a higher rate of HIV drug resistance among antiretroviral-naive individuals with unknown duration of HIV infection than previously described. Our data may be different from earlier data for the following reasons: (1) our study includes a high prevalence of HIV infections among men who have sex with men (184% of all new HIV infections in San Diego County occur among men who have sex with men [17] ), which has been linked to higher rates of transmitted drug resistance [3, 18] ; and (2) our patients may have engaged in the informal and undeclared use of antiretroviral medications. Regardless of the mechanism, the patients in our study presented to their clinical provider as antiretroviral naive. In addition, through this program, we performed 103 genotype tests; however, a total of 161 individuals received a new diagnosis of HIV infection at San Diego County HIV testing and counseling sites during the study period [19] . This lack of participation may indicate (1) that not all individuals who received a new diagnosis of HIV infection entered clinical care soon after the diagnosis, (2) that not all clinicians participated in the program, (3) that not all individuals who received a new diagnosis of HIV infection qualified for public funding for health care (e.g., individuals of undocumented legal status or who have veterans' benefits or private health insurance), or (4) a bias by individual clinicians to perform a genotype test only for those patients who were at the highest risk for acquiring drug-resistant HIV infection. Given these potential limitations and biases, we are unable to generalize these results to the population as a whole, despite capturing data for a significant number of patients who presented to their HIV care provider as antiretroviral naive.
In this study, we found many patients with highly drugresistant strains of HIV, including viruses that harbored highlevel drug resistance, such as M184V, that greatly reduce susceptibility to the commonly-used antiretrovirals lamuvidine and emtricitabine [20] . Although M184V is a common mutation in treated populations, it is very rare among individuals who are antiretroviral naive, probably because it reduces the replication capacity of the virus in the absence of antiretroviral pressure [21] . This led us to suspect that many of the patients whom the clinicians believed to be antiretroviral naive were, in fact, antiretroviral experienced. Although very little clinical data were available through the design of the study, we were able to document 2 instances (described above) of informal use of antiretroviral drugs. Although not evaluated in this study, another possible source of acquired drug resistance could be the administration of short-course antiretroviral therapy in the form of preexposure or postexposure prophylaxis to persons who unknowingly had a previously established HIV infection [22, 23] .
Cost-effectiveness modeling has revealed that HIV drug-resistance testing is at least equivalent in cost to other HIV-related medical care practices when the regional prevalence rate of primary drug resistance is 8%-10% [3, 7] . However, most public health agencies in the United States do not routinely offer drug-resistance testing to antiretroviral-naive patients, although the prevalence of primary drug resistance has been documented at rates higher than this threshold [2, 3] . Our data suggest that routine drug-resistance testing of patients who present to a health care provider stating that they are antiretroviral naive prior to initial antiretroviral therapy would be a cost-effective clinical practice, whether the duration of HIV infection is known or unknown. In addition, we recommend ongoing patient education regarding the mechanisms of antiretroviral drug resistance and routine inquiries of patients by clinicians regarding any informal use of antiretroviral drugs.
